Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
Status:
Recruiting
Trial end date:
2022-03-02
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of hydroxychloroquine and how
well it works when given together with gemcitabine and docetaxel in treating participants
with osteosarcoma that has come back or does not respond to treatment. Drugs used in
chemotherapy, such as gemcitabine, docetaxel, and hydroxychloroquine, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading.